Empowered Patient Podcast

Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its cell generation platform, including a trial for COVID-19 patients and a trial for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Dave explains, "Coeptis is a cell therapy company mainly focused on oncology, although we have recently broadened into respiratory disease. And really, the prime mission of the company would be to what we would term universalized cell therapy to make it available for the